pharmaphorum1y
Roche’s Xolair is first medicine for food allergy in US
Fast approaching the end of its patent life, Roche and Novartis’ Xolair is going out with a bang, picking up a new approval as the first and only drug therapy for people with food allergies in ...
Morningstar4d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps ...
Business Wire11d
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy (OIT) in the first-ever head-to-head trial comparing the two treatment ...
pharmaphorum3y
Blow for Novartis as ligelizumab can't top Xolair in phase 3
That hope now look decidedly faint, as ligelizumab was able to match Xolair (omalizumab) but not improve on it in a pair of phase 3 trials in CSU, although it did perform better than placebo.
ABC News11d
Some kids may successfully eat trigger foods after stopping anti-allergy med, early study suggests
More than half of children in early stages of an ongoing study were able to eat a food they were allergic to one year after stopping Xolair, a medication used for some kids with food allergies.
PharmiWeb11d
Phase III study shows Xolair may be more effective…
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to ...
Pharmabiz9d
Roche announces positive results from phase III OUtMATCH study of Xolair for the treatment of one or more food allergies
Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the role of Xolair ...
Yahoo Finance11d
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
Xolair is the only US FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies Basel, 2 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ...
Nasdaq11d
Genentech: Phase III Study Shows Xolair More Effective, Fewer Side Effects For Food Allergies
Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy (OIT) in the first-ever head-to-head trial comparing the two treatment ...
Yahoo Finance11d
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
– Xolair is the only U.S. FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies – SOUTH SAN FRANCISCO, Calif., March 02, 2025--(BUSINESS ...
Taiwan News11d
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured as late-breakers at the 2025 AAAAI Annual Meeting Xolair is the only US FDA-approved medicine to ...